A Rare Aldosterone-Producing Adenoma Detected by 68Ga-pentixafor PET-CT: A Case Report and Literature Review

Yunying Cui, Yushi Zhang, Jie Ding, Huiping Wang, Xiaoshen Ma, Ou Wang, Xiaoyan Chang, Hao Sun, Li Huo, Anli Tong, Yunying Cui, Yushi Zhang, Jie Ding, Huiping Wang, Xiaoshen Ma, Ou Wang, Xiaoyan Chang, Hao Sun, Li Huo, Anli Tong

Abstract

Context: Primary aldosteronism represents an important and common cause of hypertension and is characterized by autonomous aldosterone secretion that results in severe hypertension and hypokalemia. Nonetheless, its manifestations are atypical in some cases, which renders its diagnosis difficult. Case Description: Presented in this report is a Chinese female patient with blood pressure in the high-normal range, and her parathyroid hormone was significantly elevated. Elevated plasma aldosterone concentration plus suppressed plasma rennin activity was suggestive of primary aldosteronism. 68Ga-pentixafor positron emission tomography/computed tomography revealed an aldosterone-producing adenoma, which was globally the second of its kind ever reported so far. Moreover, the tumor was located in an extremely rare area. Conclusions: Patients with primary aldosteronism may present with normal or high-normal blood pressure and a significantly elevated parathyroid hormone. 68Ga-pentixafor PET/CT is potentially a helpful tool for the non-invasive characterization of patients with primary aldosteronism.

Keywords: 68Ga-pentixafor PET-CT; aldosterone-producing adenomas; blood pressure; parathyroid hormone; rare area.

Copyright © 2019 Cui, Zhang, Ding, Wang, Ma, Wang, Chang, Sun, Huo and Tong.

Figures

Figure 1
Figure 1
(A) CT scan revealed a 21 × 13 mm low-density mass (about 9 HU). The enhanced adrenal gland CT revealed a significant enhancement of the mass (about 70 HU). (B,C)68Ga-pentixafor PET/CT revealed that the maximum standardized uptake was 22.83.
Figure 2
Figure 2
Gross pathological, histological and immunohistochemical findings. (a) Gross pathology revealed a 61 × 27 × 8 mm golden-yellow adenoma, which was connected to the right adrenal gland. (b) Hematoxylin-eosin staining, C: Normal adrenal cortex, M: Adrenal medulla; APA: Aldosterone-producing adenoma. (c) Immunohistochemical staining with CYP11B2.

References

    1. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. . The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol. (2016) 101:1889–916. 10.1210/jc.2015-4061
    1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. . 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypert. (2018) 36:1953–2041. 10.1097/HJH.0000000000001940
    1. Brooks RV, Felix-Davies D, Lee MR, Robertson PW. Hyperaldosteronism from adrenal carcinoma. Br Med J. (1972) 1:220–1. 10.1136/bmj.1.5794.220
    1. Ito Y, Takeda R, Karashima S, Yamamoto Y, Yoneda T, Takeda Y. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res. (2011) 34:98–102. 10.1038/hr.2010.166
    1. Médeau V, Moreau F, Trinquart L, Clemessy M, Wémeau J, Vantyghem MC, et al. . Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin Endocrinol. (2008) 69:20–8. 10.1111/j.1365-2265.2008.03213.x
    1. Vantyghem MC, Ronci N, Provost F, Ghulam A, Lefebvre J, Jeunemaitre X, et al. . Aldosterone-producing adenoma without hypertension: a report of two cases. Eur J Endocrinol. (1999) 141:279–85. 10.1530/eje.0.1410279
    1. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med. (1985) 3:385–90. 10.1016/0002-9343(85)90328-6
    1. Zhang Y, Feng B. Association of serum parathyrine and calcium levels with primary aldosteronism: a meta-analysis. Int J Clin Exp Med. (2015) 8:14625–33.
    1. Jiang Y, Zhang C, Ye L, Su T, Zhou W, Jiang L, et al. . Factors affecting parathyroid hormone levels in different types of primary aldosteronism. Clin Endocrinol. (2016) 85:267–74. 10.1111/cen.12981
    1. Rossi GP, Ragazzo F, Seccia TM, Maniero C, Barisa M, Calò L A, et al. . Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension. (2012) 60:431–36. 10.1161/HYPERTENSIONAHA.112.195891
    1. Mazzocchi G, Aragona F, Malendowicz LK, Nussdorfer GG. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am J Physiol Endocrinol Metabol. (2001) 280:209–13. 10.1152/ajpendo.2001.280.2.E209
    1. Nockel PJ, Kebebew E. Epidemiology of Adrenal Neoplasms. Switzerland: Springer; (2017), 1–9. 10.1007/978-3-319-44136-8-1
    1. Lee FT, Elaraj D. Evaluation and management of primary hyperaldosteronism. Surg Clin N Am. (2019) 99:731–45. 10.1016/j.suc.2019.04.010
    1. Simon DR, Palese MA. Noninvasive adrenal imaging in hyperaldosteronism. Curr Urol Rep. (2008) 9:80–7. 10.1007/s11934-008-0015-2
    1. Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specificity of 11C-Metomidate Positron Emission Tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metabol. (2012) 97:100–9. 10.1210/jc.2011-1537
    1. Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, Mustafa M, et al. . Targeting CXCR4 (CXC Chemokine Receptor Type 4) for molecular imaging of aldosterone-producing adenoma. Hypertension. (2018) 71:317–25. 10.1161/HYPERTENSIONAHA.117.09975
    1. Powlson AS, Gurnell M, Brown MJ. Nuclear imaging in the diagnosis of primary aldosteronism. Curr Opin Endocrinol Diabet Obesity. (2015) 22:150–6. 10.1097/MED.0000000000000148

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する